LEADER 01315aam 2200385I 450 001 9910709949603321 005 20151030104351.0 024 8 $aGOVPUB-C13-eefc8d2e1f9ab9032a3b82f301d8b2c7 035 $a(CKB)5470000002474771 035 $a(OCoLC)927168420 035 $a(EXLCZ)995470000002474771 100 $a20151030d1940 ua 0 101 0 $aeng 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aAir infilteration through windows /$fEugene F. Coleman, Roy H. Heald 210 1$aGaithersburg, MD :$cU.S. Dept. of Commerce, National Institute of Standards and Technology,$d1940. 215 $a1 online resource 225 1 $aBuilding materials and structures report ;$v45 300 $a1940. 300 $aContributed record: Metadata reviewed, not verified. Some fields updated by batch processes. 300 $aTitle from PDF title page. 320 $aIncludes bibliographical references. 700 $aColeman$b Eugene F$01401600 701 $aColeman$b Eugene F$01401600 701 $aHeald$b R. H$01401601 712 02$aUnited States.$bNational Bureau of Standards. 801 0$bNBS 801 1$bNBS 801 2$bGPO 906 $aBOOK 912 $a9910709949603321 996 $aAir infilteration through windows$93470440 997 $aUNINA LEADER 04858nam 22006015 450 001 9910254558403321 005 20200702165428.0 010 $a4-431-55031-3 024 7 $a10.1007/978-4-431-55031-0 035 $a(CKB)3150000000021361 035 $a(EBL)4419966 035 $a(SSID)ssj0001653537 035 $a(PQKBManifestationID)16432940 035 $a(PQKBTitleCode)TC0001653537 035 $a(PQKBWorkID)14982666 035 $a(PQKB)10826546 035 $a(DE-He213)978-4-431-55031-0 035 $a(MiAaPQ)EBC4419966 035 $a(PPN)192217534 035 $a(EXLCZ)993150000000021361 100 $a20160222d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aImmunotherapy of Cancer $eAn Innovative Treatment Comes of Age /$fedited by Yoshiyuki Yamaguchi 205 $a1st ed. 2016. 210 1$aTokyo :$cSpringer Japan :$cImprint: Springer,$d2016. 215 $a1 online resource (351 p.) 300 $aDescription based upon print version of record. 311 $a4-431-55030-5 320 $aIncludes bibliographical references. 327 $aPart I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 ??-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 ?? T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. 330 $aThis timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival. 606 $aOncology   606 $aCancer research 606 $aImmunology 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 615 0$aOncology  . 615 0$aCancer research. 615 0$aImmunology. 615 14$aOncology. 615 24$aCancer Research. 615 24$aImmunology. 676 $a616.994079 702 $aYamaguchi$b Yoshiyuki$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910254558403321 996 $aImmunotherapy of Cancer$92519904 997 $aUNINA